MedTrace Logo

The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma

NCT03016988 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-01-11

No results posted yet for this study

Summary

Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma (NHL) and shows poor survival. This study to evaluate the efficacy and safety of Bortezomib combined with Fludarabine and Cytarabine treatment in the naive and relapsed MCL who are not eligible for high dose therapy and transplantation.

Conditions

Interventions

DRUG

Bortezomib

Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11;

DRUG

Fludarabine

Fludarabine(F) 25mg/m2, intravenously day 1-3;

DRUG

Cytarabine

Cytarabine(A) 500mg/m2 for 3 days(day1-3)

Sponsors & Collaborators

  • Union hospital of Fujian Medical University

    collaborator OTHER

  • Tingbo Liu

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2018-12-31
Completion
2020-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03016988 on ClinicalTrials.gov